Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Alnylam Pharmaceuticals, Inc., Medpace Holdings or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Alnylam Pharmaceuticals, Inc., Medpace Holdings and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Alnylam Pharmaceuticals, Inc., Medpace Holdings and Inc.

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer’s disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington’s disease; ALN-5288 for Alzheimer’s disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson’s disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

Latest Biotechnology and Alnylam Pharmaceuticals, Inc., Medpace Holdings, Inc. Stock News

As of July 30, 2026, Alnylam Pharmaceuticals, Inc. had a $27.4 billion market capitalization, compared to the Biotechnology median of $251.9 million. Alnylam Pharmaceuticals, Inc.’s stock is down 48.3% in 2026, down 24.4% in the previous five trading days and down 37.84% in the past year.

Currently, Alnylam Pharmaceuticals, Inc.’s price-earnings ratio is 52.0. Alnylam Pharmaceuticals, Inc.’s trailing 12-month revenue is $4.3 billion with a 12.5% net profit margin. Year-over-year quarterly sales growth most recently was 96.4%. Analysts expect adjusted earnings to reach $8.971 per share for the current fiscal year. Alnylam Pharmaceuticals, Inc. does not currently pay a dividend.

As of July 30, 2026, Medpace Holdings, Inc. had a $16.1 billion market cap, putting it in the 84th percentile of all stocks. Medpace Holdings, Inc.’s stock is up 2.8% in 2026, down 4% in the previous five trading days and up 29.11% in the past year.

Currently, Medpace Holdings, Inc.’s price-earnings ratio is 33.9. Medpace Holdings, Inc.’s trailing 12-month revenue is $2.8 billion with a 17.7% net profit margin. Year-over-year quarterly sales growth most recently was 17.2%. Analysts expect adjusted earnings to reach $17.705 per share for the current fiscal year. Medpace Holdings, Inc. does not currently pay a dividend.

How We Compare Alnylam Pharmaceuticals, Inc., Medpace Holdings and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Alnylam Pharmaceuticals, Inc., Medpace Holdings and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Alnylam Pharmaceuticals, Inc., Medpace Holdings and Inc. Stock Value Grades

Company	Ticker	Value
Alnylam Pharmaceuticals, Inc.	ALNY	F
Medpace Holdings, Inc.	MEDP	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Alnylam Pharmaceuticals, Inc. has a Value Score of 5, which is Ultra Expensive. Medpace Holdings, Inc. has a Value Score of 17, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither Alnylam Pharmaceuticals, Inc., Medpace Holdings or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Alnylam Pharmaceuticals, Inc., Medpace Holdings or Inc. is the better investment when it comes to value.

Alnylam Pharmaceuticals, Inc., Medpace Holdings and Inc. Growth Grades

Company	Ticker	Growth
Alnylam Pharmaceuticals, Inc.	ALNY	D
Medpace Holdings, Inc.	MEDP	B

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Alnylam Pharmaceuticals, Inc. has a Growth Score of 32, which is Weak. Medpace Holdings, Inc. has a Growth Score of 69, which is Strong.

The Growth Grade Winner: Medpace Holdings, Inc.

As you can clearly see from the Growth Grade breakdown above, Medpace Holdings, Inc. has a more attractive growth grade than Alnylam Pharmaceuticals, Inc.. For investors who focus solely on how a company is growing relative to other companies in the same industry, Medpace Holdings, Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Alnylam Pharmaceuticals, Inc., Medpace Holdings and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Alnylam Pharmaceuticals, Inc.	ALNY	D
Medpace Holdings, Inc.	MEDP	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Alnylam Pharmaceuticals, Inc. has a Earnings Estimate Score of 31, which is Negative. Medpace Holdings, Inc. has a Earnings Estimate Score of 63, which is Positive.

The Earnings Estimate Revisions Grade Winner: Medpace Holdings, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Medpace Holdings, Inc. has a better Earnings Estimate Revisions Grade than Alnylam Pharmaceuticals, Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Medpace Holdings, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Alnylam Pharmaceuticals, Inc., Medpace Holdings and Inc. Grades

In addition to Value, Estimate Revisions and Growth, A+ Investor also provides grades for Momentum and Quality.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Alnylam Pharmaceuticals, Inc., Medpace Holdings and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Alnylam Pharmaceuticals, Inc., Medpace Holdings or Inc. Stock?

Overall, Alnylam Pharmaceuticals, Inc. stock has a Value Score of 5, Growth Score of 32 and Estimate Revisions Score of 31.

Medpace Holdings, Inc. stock has a Value Score of 17, Growth Score of 69 and Estimate Revisions Score of 63.

Comparing Alnylam Pharmaceuticals, Inc., Medpace Holdings and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.